WaveMan
WaveMan · Company
ACRV · Acrivon Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ACRV Acrivon Therapeutics (ACRV) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001781174
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
26
13F, latest reported quarter

What the filings say about ACRV

Insiders, 180 days
-$41.3K net sold
6 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$30.6K
1 notice

Acrivon Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Acrivon Therapeutics, Inc. insiders sold a net $41.3K of stock across 27 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Miller Mary
Chief Legal Officer
SELL
2026-10-26 SECtraded 2026-10-22
513
$944
n/a
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Oct 5, 2026.
  • The trade is 0.6% of the 81,202 shares held after it.
  • No other insider sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Miller Mary sold about $944 of ACRV on Oct 22, 2026; 26 funds added in the latest 13F quarter.
Miller Mary
Chief Legal Officer
SELL
2026-10-07 SECtraded 2026-10-05
294
$585
-8.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 18, 2026.
  • The trade is 0.4% of the 81,715 shares held after it.
  • No other insider sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Miller Mary sold about $585 of ACRV on Oct 5, 2026; 26 funds added in the latest 13F quarter.
Blume-Jensen Peter
President and CEO
SELL
2026-08-27 SECtraded 2026-08-25
14,036
$31.0K
-16.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Aug 18, 2026.
  • The trade is 0.6% of the 2,230,052 shares held after it.
  • 5 other insiders sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Blume-Jensen Peter sold about $31.0K of ACRV on Aug 25, 2026, the largest insider sale at the company since 2025; 5 other insiders sold within 30 days and 26 funds added in the latest 13F quarter.
Devroe Eric
Chief Operating Officer
SELL
2026-08-20 SECtraded 2026-08-18
604
$1.2K
-22.2%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 13, 2026.
  • The trade is 0.4% of the 146,349 shares held after it.
  • 5 other insiders sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Devroe Eric sold about $1.2K of ACRV on Aug 18, 2026; 5 other insiders sold within 30 days and 26 funds added in the latest 13F quarter.
Blume-Jensen Peter
President and CEO
SELL
2026-08-20 SECtraded 2026-08-18
1,229
$2.5K
-22.2%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 14, 2026.
  • The trade is 0.1% of the 2,244,088 shares held after it.
  • 5 other insiders sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Blume-Jensen Peter sold about $2.5K of ACRV on Aug 18, 2026, the largest insider sale at the company since 2025; 5 other insiders sold within 30 days and 26 funds added in the latest 13F quarter.
27 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 22 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$41.3K over 180 days
-$40.3K over 90 days
more than 57% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
26 funds bought in last quarter
below 64% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.3% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
below 55% of Pharma & Biotech
What changed in the last 30 days
Oct 26Chief Legal Officer Miller Mary sold $1.5K (2 trades, Oct 5 to Oct 22)

Watch ACRV

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-13.6%12M
-35%-6%+22%+51%2025-102025-122026-022026-042026-062026-082026-10 2026-01-14 · Blume-Jensen Peter bought $82.3K2026-08-25 · Blume-Jensen Peter sold $31.0K2026-01-13 · Devroe Eric bought $17.2K2026-01-14 · Levy Adam D. bought $15.0K2026-08-18 · Blume-Jensen Peter sold $2.5K2026-08-04 · Levy Adam D. sold $1.8K2026-08-18 · Devroe Eric sold $1.2K2026-07-21 · Miller Mary sold $1.0K2026-08-18 · Blume-Jensen Peter sold $9732026-10-22 · Miller Mary sold $9442026-08-18 · Gamelin Erick sold $8042026-10-05 · Miller Mary sold $5852026-08-18 · Miller Mary sold $3722026-08-18 · Peterson Katharine sold $2032026-08-25 · Peter Blume-Jensen filed to sell $30.6K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ACRV: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
12,229,396 sh
$21.8M
Sands Capital Alternatives, LLC
2,289,271 sh
$4.1M
VANGUARD CAPITAL MANAGEMENT LLC
952,008 sh
$1.7M
WELLINGTON MANAGEMENT GROUP LLP
888,130 sh
$1.6M
RENAISSANCE TECHNOLOGIES LLC
758,863 sh
$1.4M

Congress trades in ACRV

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ACRV planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Peter Blume-Jensen
Filed 2026-08-25
$30.6K

ACRV mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$562.5K position · as of 2026-06-30
0.6%
Ultra-Small Company Market Fund
$103.2K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$131.5K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$8.8K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$693.4K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$178.1K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 2
1 active
1
Multi-phase
1 active
What changed recently
Study of ACR-2316 in Specific Advanced Solid Tumors
2026-09-22 · Completion moved 2026-08-12 → 2027-08-12
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $41.3K sold by insiders over 180 days, 26 funds added last quarter, $30.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ACRV financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$64.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-64.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-57.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-67.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-87.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$84.1M-$89.2M-$67.1M-$32.7M
Net income-$77.9M-$80.6M-$60.4M-$31.2M
EPS (diluted)-2.02-2.38-2.74-7.56
Operating cash flow-$63.7M-$65.7M-$42.6M-$30.1M
Cash$41.5M$39.8M$36.0M$29.5M
SEC XBRL, fiscal years, as known on 2026-10-27

ACRV Stock Sonar score 4/7 axes

Find similar shapesCompare

ACRV ranks highest on risk and compliance (53rd percentile) and profitability (41st), and lowest on insider conviction (28th), among Pharma & Biotech peers.

Profitability
41
Inputs
  • Return on equity-64.6% · 45 pct, sector of 545
  • Return on assets-57.6% · 39 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-67.3% · 37 pct, sector of 576
Insider conviction
28
Inputs
  • Net Form 4 buying (codes P and S), 180d-$41K · 56 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
36
Inputs
  • Funds adding, latest quarter26 · 36 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
53
Inputs
  • Short interest, % of float+6.3% · 53 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ACRV filings, in plain words

Are Acrivon Therapeutics insiders buying or selling ACRV?

In the 180 days to 2026-10-27, Acrivon Therapeutics insiders were net sellers, a net $41.3K across purchases and sales reported on Form 4, by 6 sellers.

Are there planned insider sales of ACRV?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $30.6K of stock; the latest, by Peter Blume-Jensen, was filed 2026-08-25.

Read the full summary

In the 180 days to 2026-10-27, Acrivon Therapeutics insiders were net sellers of ACRV, a net $41.3K across purchases and sales reported on Form 4 by 6 sellers. None of the 11 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $30.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies